Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients

Wang, Bin; Lu, Jinsen; Wang, Zhi Hui; Wang, Hong

doi:10.14744/anatoljcardiol.2017.27020

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In spite of numerous investigations involving many P-gp substrates, the role of these SNPs in protein expression and functional integrity, as well as their importance for drug therapy, is still stirring up controversy. Contradictory results include studies that have reported lower P-gp expression, higher drug levels, or more pronounced effects in carriers of variant alleles [ 9 ], as opposed to others, where the observed effects were partly or entirely inverse [ 10 ], or not detected at all [ 11 ]. Clopidogrel studies yielded conflicting conclusions too, with observations of lower drug plasma concentration, impaired response to therapy, and a higher risk of bleeding in carriers of variant 3435T allele [ 12 ], counterbalanced by the opposite findings lacking any significant association of ABCB1 polymorphism with clopidogrel pharmacokinetics or platelet response [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

ABCB1 polymorphism in clopidogrel-treated Montenegrin patients

Mugosa

Todorović

Cukic³

et al. 2021

Open Life Sciences

View full text Add to dashboard Cite

Clopidogrel is an antiplatelet drug that displays significant interindividual variability in treatment response. Its bioavailability depends on the function of P-glycoprotein (P-gp), which is coded by a highly polymorphic ABCB1 gene. Thus, the aim of this study was to investigate the effect of ABCB1 genetic polymorphism on clopidogrel efficacy and safety and to determine the frequency distribution of its most common single nucleotide polymorphisms (SNPs) in 106 Montenegrin cardiology patients. Clopidogrel efficacy and safety were followed up during 1 year after hospitalization, with the lack of efficacy and adverse drug reactions observed in 11 (10.4%) and 8 patients (7.5%), respectively. Genotyping for ABCB1 SNPs rs1128503 (1236C > T), rs2032582 (2677G > A/T), and rs1045642 (3435C > T) was performed by the real-time PCR method, and the variant alleles were detected with the frequencies of 42.9, 44.8, and 52.8%, respectively. No significant association was observed between any of the examined genotypes and clopidogrel efficacy (p = 0.253) or safety (p = 0.424). Due to small sample size, co-treatment with other drugs, and other genetic factors not taken into account, we believe the absence of correlation between ABCB1 genotypes and indicators of clopidogrel efficacy and safety in this study should be apprehended conditionally, and that larger and better-controlled studies are warranted.

show abstract